Association Between User Engagement of a Mobile Health App for Gout and Improvements in Self-Care Behaviors: Randomized Controlled Trial.


Journal

JMIR mHealth and uHealth
ISSN: 2291-5222
Titre abrégé: JMIR Mhealth Uhealth
Pays: Canada
ID NLM: 101624439

Informations de publication

Date de publication:
13 08 2019
Historique:
received: 13 06 2019
accepted: 04 07 2019
revised: 04 07 2019
entrez: 15 8 2019
pubmed: 15 8 2019
medline: 25 8 2020
Statut: epublish

Résumé

Mobile health (mHealth) apps represent a promising approach for improving health outcomes in patients with chronic illness, but surprisingly few mHealth interventions have investigated the association between user engagement and health outcomes. We aimed to examine the efficacy of a recommended, commercially available gout self-management app for improving self-care behaviors and to assess self-reported user engagement of the app in a sample of adults with gout. Our objective was to examine differences in self-reported user engagement between a recommended gout app (treatment group) and a dietary app (active control group) over 2 weeks as well as to examine any differences in self-care behaviors and illness perceptions. Seventy-two adults with gout were recruited from the community and three primary and secondary clinics. Participants were randomized to use either Gout Central (n=36), a self-management app, or the Dietary Approaches to Stop Hypertension Diet Plan (n=36), an app based on a diet developed for hypertension, for 2 weeks. The user version of the Mobile Application Rating Scale (uMARS, scale: 1 to 5) was used after the 2 weeks to assess self-reported user engagement, which included an open-ended question. Participants also completed a self-report questionnaire on self-care behaviors (scale: 1-5 for medication adherence and diet and 0-7 for exercise) and illness perceptions (scale: 0-10) at baseline and after the 2-week trial. Independent samples t tests and analysis of covariance were used to examine differences between groups at baseline and postintervention. Participants rated the gout app as more engaging (mean difference -0.58, 95% CI -0.96 to -0.21) and more informative (mean difference -0.34, 95% CI -0.67 to -0.01) than the dietary app at the 2-week follow-up. The gout app group also reported a higher awareness of the importance of gout (mean difference -0.64, 95% CI -1.27 to -0.003) and higher knowledge/understanding of gout (mean difference -0.70, 95% CI -1.30 to -0.09) than the diet app group at follow-up. There were no significant differences in self-care behaviors between the two groups postintervention. The gout app group also demonstrated stronger negative beliefs regarding the impact of gout (mean difference -2.43, 95% CI -3.68 to -1.18), stronger beliefs regarding the severity of symptoms (mean difference -1.97, 95% CI -3.12 to -0.82), and a stronger emotional response to gout (mean difference -2.38, 95% CI -3.85 to -0.90) at follow-up. Participant feedback highlighted the importance of tracking health-related information, customizing to the target group/individual, providing more interactive features, and simplifying information. Participants found the commercially available gout app more engaging. However, these findings did not translate into differences in self-care behaviors. The gout app group also demonstrated stronger negative illness perceptions at the follow-up. Overall, these findings suggest that the development of gout apps would benefit from a user-centered approach with a focus on daily, long-term self-care behaviors as well as modifying illness beliefs. Australian New Zealand Clinical Trials Registry ACTRN12617001052325; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373217.

Sections du résumé

BACKGROUND
Mobile health (mHealth) apps represent a promising approach for improving health outcomes in patients with chronic illness, but surprisingly few mHealth interventions have investigated the association between user engagement and health outcomes. We aimed to examine the efficacy of a recommended, commercially available gout self-management app for improving self-care behaviors and to assess self-reported user engagement of the app in a sample of adults with gout.
OBJECTIVE
Our objective was to examine differences in self-reported user engagement between a recommended gout app (treatment group) and a dietary app (active control group) over 2 weeks as well as to examine any differences in self-care behaviors and illness perceptions.
METHODS
Seventy-two adults with gout were recruited from the community and three primary and secondary clinics. Participants were randomized to use either Gout Central (n=36), a self-management app, or the Dietary Approaches to Stop Hypertension Diet Plan (n=36), an app based on a diet developed for hypertension, for 2 weeks. The user version of the Mobile Application Rating Scale (uMARS, scale: 1 to 5) was used after the 2 weeks to assess self-reported user engagement, which included an open-ended question. Participants also completed a self-report questionnaire on self-care behaviors (scale: 1-5 for medication adherence and diet and 0-7 for exercise) and illness perceptions (scale: 0-10) at baseline and after the 2-week trial. Independent samples t tests and analysis of covariance were used to examine differences between groups at baseline and postintervention.
RESULTS
Participants rated the gout app as more engaging (mean difference -0.58, 95% CI -0.96 to -0.21) and more informative (mean difference -0.34, 95% CI -0.67 to -0.01) than the dietary app at the 2-week follow-up. The gout app group also reported a higher awareness of the importance of gout (mean difference -0.64, 95% CI -1.27 to -0.003) and higher knowledge/understanding of gout (mean difference -0.70, 95% CI -1.30 to -0.09) than the diet app group at follow-up. There were no significant differences in self-care behaviors between the two groups postintervention. The gout app group also demonstrated stronger negative beliefs regarding the impact of gout (mean difference -2.43, 95% CI -3.68 to -1.18), stronger beliefs regarding the severity of symptoms (mean difference -1.97, 95% CI -3.12 to -0.82), and a stronger emotional response to gout (mean difference -2.38, 95% CI -3.85 to -0.90) at follow-up. Participant feedback highlighted the importance of tracking health-related information, customizing to the target group/individual, providing more interactive features, and simplifying information.
CONCLUSIONS
Participants found the commercially available gout app more engaging. However, these findings did not translate into differences in self-care behaviors. The gout app group also demonstrated stronger negative illness perceptions at the follow-up. Overall, these findings suggest that the development of gout apps would benefit from a user-centered approach with a focus on daily, long-term self-care behaviors as well as modifying illness beliefs.
TRIAL REGISTRATION
Australian New Zealand Clinical Trials Registry ACTRN12617001052325; https://anzctr.org.au/Trial/Registration/TrialReview.aspx?id=373217.

Identifiants

pubmed: 31411147
pii: v7i8e15021
doi: 10.2196/15021
pmc: PMC6711037
doi:

Banques de données

ANZCTR
['ACTRN12617001052325']

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e15021

Informations de copyright

©Anna Serlachius, Kiralee Schache, Anel Kieser, Bruce Arroll, Keith Petrie, Nicola Dalbeth. Originally published in JMIR Mhealth and Uhealth (http://mhealth.jmir.org), 13.08.2019.

Références

Qual Health Res. 2005 Nov;15(9):1277-88
pubmed: 16204405
J Psychosom Res. 2006 Jun;60(6):631-7
pubmed: 16731240
Arthritis Rheum. 2011 Oct;63(10):3136-41
pubmed: 21800283
Curr Diab Rep. 2011 Dec;11(6):486-93
pubmed: 21960031
Arthritis Care Res (Hoboken). 2011 Nov;63(11):1605-12
pubmed: 22034122
Br J Health Psychol. 2012 Feb;17(1):74-84
pubmed: 22107110
J Med Internet Res. 2012 May 14;14(3):e72
pubmed: 22584372
BMC Musculoskelet Disord. 2012 Sep 16;13:174
pubmed: 22978848
Health Educ Behav. 2013 Apr;40(2):133-9
pubmed: 22991048
Biomed Instrum Technol. 2012 Fall;Suppl:49-56
pubmed: 23039777
Transl Behav Med. 2013 Sep;3(3):271-6
pubmed: 24073178
J Med Internet Res. 2013 Nov 15;15(11):e247
pubmed: 24240579
J Clin Rheumatol. 2014 Apr;20(3):172-4
pubmed: 24662562
Arthritis Care Res (Hoboken). 2014 Oct;66(10):1551-9
pubmed: 24692321
Telemed J E Health. 2014 Jun;20(6):570-83
pubmed: 24787747
Am J Prev Med. 2014 Jun;46(6):649-52
pubmed: 24842742
AIDS Patient Care STDS. 2014 Nov;28(11):579-86
pubmed: 25290556
J Med Internet Res. 2015 Jan 30;17(1):e30
pubmed: 25639757
JMIR Mhealth Uhealth. 2015 Mar 11;3(1):e27
pubmed: 25760773
Acad Emerg Med. 2015 Jun;22(6):754-6
pubmed: 25997375
Stat Methods Med Res. 2016 Jun;25(3):1057-73
pubmed: 26092476
Nat Rev Rheumatol. 2015 Nov;11(11):649-62
pubmed: 26150127
Ann Rheum Dis. 2015 Oct;74(10):1789-98
pubmed: 26359487
JMIR Mhealth Uhealth. 2015 Nov 04;3(4):e101
pubmed: 26537656
J Adv Nurs. 2016 Apr;72(4):849-63
pubmed: 26689295
JMIR Mhealth Uhealth. 2016 Jun 10;4(2):e72
pubmed: 27287964
Int J Med Inform. 2016 Oct;94:67-74
pubmed: 27573313
Am J Prev Med. 2016 Nov;51(5):833-842
pubmed: 27745683
Arthritis Care Res (Hoboken). 2017 Sep;69(9):1444-1448
pubmed: 27813363
BMJ. 2017 May 9;357:j1794
pubmed: 28487277
JMIR Mhealth Uhealth. 2017 Jun 29;5(6):e89
pubmed: 28663164
BMC Musculoskelet Disord. 2017 Nov 23;18(1):488
pubmed: 29169350
Semin Arthritis Rheum. 2018 Apr;47(5):689-702
pubmed: 29198878
BMJ. 2018 May 17;361:k1959
pubmed: 29773539
Telemed J E Health. 2019 Apr;25(4):272-273
pubmed: 29969385
JMIR Mhealth Uhealth. 2018 Oct 15;6(10):e182
pubmed: 30322835
Front Psychiatry. 2018 Oct 18;9:481
pubmed: 30405450
N Z Med J. 2018 Nov 9;131(1485):8-12
pubmed: 30408813
JMIR Mhealth Uhealth. 2019 Jan 23;7(1):e9836
pubmed: 30672742
J Behav Med. 1997 Jun;20(3):291-312
pubmed: 9212382

Auteurs

Anna Serlachius (A)

Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Kiralee Schache (K)

Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Anel Kieser (A)

Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Bruce Arroll (B)

General Practice and Primary Healthcare, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Keith Petrie (K)

Department of Psychological Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Nicola Dalbeth (N)

Bone and Joint Research Group, Department of Medicine, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH